Tag Archives: First

Tremfya (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis

Print this page HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] Tremfya is the first treatment… Read More »

A trial is under way of the first new antibody medicine developed to treat covid-19 – MIT Technology Review

The news: Patients have started to receive the first antibody drug developed specifically to treat covid-19. It’s being tested in 32 patients at various doses in hospitals in the US. If it’s shown to be safe, the drug, referred to as LY-CoV555, will be studied in non-hospitalized coronavirus patients later this summer. The big idea:… Read More »

First map of tumour microbiomes finds bacteria live in many cancers

By Alice Klein More than 60 per cent of pancreatic tumours tested positive for bacterial DNAANNE WESTON, FRANCIS CRICK INSTITUTE / SCIENCE PHOTO LIBRARY The first comprehensive survey of the microorganisms that live inside tumours has found that bacteria reside in those from many different cancer types, but it is unclear whether they contribute to… Read More »

FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis

Print this page TARRYTOWN, N.Y. and PARIS, May 26, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not… Read More »

House panel to hold hearing on VA delay of first EHR go-live

The chair of the House subcommittee charged with legislative oversight of the VA’s Cerner electronic health record implementation is concerned about the agency’s decision to delay the EHR’s initial go-live. “I’m concerned that as we’ve moved closer to the go-live date, we have been told repeatedly that there were no showstoppers in the implementation, that… Read More »

NSW virus ‘first wave’ may hit 20 per cent

Up to 1.6 million people in NSW could be hit by the first wave of a statewide coronavirus outbreak, health authorities warn, with up to 80,000 people likely to require intensive care simultaneously. Chief health officer Dr Kerry Chant says preparations are underway for 20 per cent of the state’s eight million residents to catch… Read More »

  1. Pages:
  3. 1
  4. 2
  5. 3
  6. 4
  7. 5
  8. 6
  9. 7
  10. ...
  11. 12